Altimmune Capital Stock from 2010 to 2024

ALT Stock

USD 8.25 0.07 0.86%

Altimmune Capital Stock yearly trend continues to be comparatively stable with very little volatility. Capital Stock will likely drop to 4,065 in 2024. Capital Stock is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. View All Fundamentals

Capital Stock

First Reported

2010-12-31

Previous Quarter

7 K

Current Value

4.1 K

Quarterly Volatility

2 K

Credit Downgrade

Yuan Drop

Covid

Check Altimmune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Altimmune's main balance sheet or income statement drivers, such as Interest Expense of 33.2 K, Selling General Administrative of 13.5 M or Total Revenue of 404.7 K, as well as many indicators such as Price To Sales Ratio of 1.5 K, Dividend Yield of 0.0 or PTB Ratio of 3.24. Altimmune financial statements analysis is a perfect complement when working with Altimmune Valuation or Volatility modules.

Check out the analysis of Altimmune Correlation against competitors.

For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.

Latest Altimmune's Capital Stock Growth Pattern

Below is the plot of the Capital Stock of Altimmune over the last few years. It is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. Altimmune's Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Altimmune's overall financial position and show how it may be relating to other accounts over time.

Capital Stock

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Capital Stock

Timeline

Altimmune Capital Stock Regression Statistics

	Arithmetic Mean	2,216
	Geometric Mean	1,583
	Coefficient Of Variation	90.58
	Mean Deviation	1,703
	Median	876.00
	Standard Deviation	2,008
	Sample Variance	4M
	Range	6.1K
	R-Value	0.81
	Mean Square Error	1.5M
	R-Squared	0.66
	Significance	0.0002
	Slope	365.24
	Total Sum of Squares	56.4M

Altimmune Capital Stock History

	2024	4064.69
	2023	7000.0
	2022	5000.0
	2021	4090.0
	2020	3697.0
	2019	1508.0

Other Fundumenentals of Altimmune

Issuance Of Capital Stock

Altimmune Capital Stock component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Short Term Debt	Net Receivables	Short Term Investments	Intangible Assets	Net Tangible Assets	Long Term Debt	Capital Surpluse	Deferred Long Term Liab	Property Plant Equipment	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.85	-0.94	-0.42	0.46	0.45	0.99	0.2	0.19	-0.25	0.18	0.81	0.26	0.85	0.15	0.65	-0.44	0.59	0.01	-0.53	0.83	0.83	0.77
Total Stockholder Equity	0.85		-0.75	-0.64	0.49	-0.09	0.83	0.01	0.26	-0.42	0.35	0.68	0.19	0.98	0.23	0.89	-0.37	0.82	0.17	-0.72	0.97	0.97	0.89
Net Debt	-0.94	-0.75		0.48	-0.49	-0.48	-0.94	-0.35	-0.42	0.14	-0.04	-0.62	-0.19	-0.8	-0.05	-0.63	0.52	-0.53	0.15	0.43	-0.78	-0.78	-0.73
Retained Earnings	-0.42	-0.64	0.48		-0.67	0.26	-0.45	-0.47	-0.13	0.03	0.07	-0.31	0.06	-0.73	-0.02	-0.89	0.42	-0.7	0.12	0.4	-0.67	-0.68	-0.81
Accounts Payable	0.46	0.49	-0.49	-0.67		0.03	0.47	0.4	0.18	0.18	-0.09	0.33	-0.11	0.53	-0.03	0.6	-0.3	0.49	-0.14	-0.25	0.56	0.56	0.64
Total Liab	0.45	-0.09	-0.48	0.26	0.03		0.46	0.35	-0.08	0.24	-0.26	0.39	0.16	-0.05	-0.12	-0.28	-0.21	-0.27	-0.26	0.22	-0.07	-0.08	-0.07
Total Current Assets	0.99	0.83	-0.94	-0.45	0.47	0.46		0.26	0.18	-0.2	0.13	0.81	0.17	0.85	0.05	0.66	-0.5	0.58	-0.08	-0.46	0.82	0.82	0.77
Common Stock	0.2	0.01	-0.35	-0.47	0.4	0.35	0.26		0.01	0.43	-0.36	0.12	-0.22	0.15	-0.42	0.23	-0.34	-0.18	-0.61	0.43	0.16	0.16	0.27
Current Deferred Revenue	0.19	0.26	-0.42	-0.13	0.18	-0.08	0.18	0.01		0.02	0.09	-0.35	-0.1	0.25	-0.06	0.26	-0.12	0.13	-0.08	-0.12	0.31	0.28	0.17
Short Term Debt	-0.25	-0.42	0.14	0.03	0.18	0.24	-0.2	0.43	0.02		-0.01	-0.23	-0.58	-0.33	-0.36	-0.26	0.06	-0.39	-0.32	0.54	-0.3	-0.31	-0.28
Net Receivables	0.18	0.35	-0.04	0.07	-0.09	-0.26	0.13	-0.36	0.09	-0.01		0.15	0.25	0.28	0.5	0.14	0.46	0.17	0.66	-0.36	0.34	0.33	0.13
Short Term Investments	0.81	0.68	-0.62	-0.31	0.33	0.39	0.81	0.12	-0.35	-0.23	0.15		0.19	0.7	0.13	0.47	-0.48	0.5	-0.01	-0.48	0.66	0.67	0.62
Intangible Assets	0.26	0.19	-0.19	0.06	-0.11	0.16	0.17	-0.22	-0.1	-0.58	0.25	0.19		0.14	0.8	-0.03	0.37	0.12	0.65	-0.51	0.14	0.14	0.14
Net Tangible Assets	0.85	0.98	-0.8	-0.73	0.53	-0.05	0.85	0.15	0.25	-0.33	0.28	0.7	0.14		0.18	0.92	-0.47	0.81	0.06	-0.69	0.97	0.98	0.92
Long Term Debt	0.15	0.23	-0.05	-0.02	-0.03	-0.12	0.05	-0.42	-0.06	-0.36	0.5	0.13	0.8	0.18		0.05	0.45	0.25	0.85	-0.68	0.19	0.19	0.17
Capital Surpluse	0.65	0.89	-0.63	-0.89	0.6	-0.28	0.66	0.23	0.26	-0.26	0.14	0.47	-0.03	0.92	0.05		-0.44	0.83	-0.02	-0.56	0.88	0.88	0.91
Deferred Long Term Liab	-0.44	-0.37	0.52	0.42	-0.3	-0.21	-0.5	-0.34	-0.12	0.06	0.46	-0.48	0.37	-0.47	0.45	-0.44		-0.35	0.7	0.1	-0.44	-0.45	-0.42
Property Plant Equipment	0.59	0.82	-0.53	-0.7	0.49	-0.27	0.58	-0.18	0.13	-0.39	0.17	0.5	0.12	0.81	0.25	0.83	-0.35		0.26	-0.81	0.73	0.75	0.82
Long Term Debt Total	0.01	0.17	0.15	0.12	-0.14	-0.26	-0.08	-0.61	-0.08	-0.32	0.66	-0.01	0.65	0.06	0.85	-0.02	0.7	0.26		-0.57	0.05	0.05	0.05
Short Long Term Debt	-0.53	-0.72	0.43	0.4	-0.25	0.22	-0.46	0.43	-0.12	0.54	-0.36	-0.48	-0.51	-0.69	-0.68	-0.56	0.1	-0.81	-0.57		-0.66	-0.67	-0.64
Net Invested Capital	0.83	0.97	-0.78	-0.67	0.56	-0.07	0.82	0.16	0.31	-0.3	0.34	0.66	0.14	0.97	0.19	0.88	-0.44	0.73	0.05	-0.66		1.0	0.91
Net Working Capital	0.83	0.97	-0.78	-0.68	0.56	-0.08	0.82	0.16	0.28	-0.31	0.33	0.67	0.14	0.98	0.19	0.88	-0.45	0.75	0.05	-0.67	1.0		0.92
Capital Stock	0.77	0.89	-0.73	-0.81	0.64	-0.07	0.77	0.27	0.17	-0.28	0.13	0.62	0.14	0.92	0.17	0.91	-0.42	0.82	0.05	-0.64	0.91	0.92

Click cells to compare fundamentals

About Altimmune Financial Statements

Altimmune shareholders use historical fundamental indicators, such as Capital Stock, to determine how well the company is positioned to perform in the future. Although Altimmune investors may analyze each financial statement separately, they are all interrelated. The changes in Altimmune's assets and liabilities, for example, are also reflected in the revenues and expenses on on Altimmune's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Capital Stock	7 K	4.1 K
Issuance Of Capital Stock	86.8 M	78.9 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Altimmune Stock Analysis

When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Altimmune Capital Stock from 2010 to 2024

Latest Altimmune's Capital Stock Growth Pattern

Altimmune Capital Stock Regression Statistics

Altimmune Capital Stock History

Other Fundumenentals of Altimmune

Altimmune Capital Stock component correlations

About Altimmune Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Altimmune Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY